Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,

#1687 Pancreatic well-differentiated neuroendocrine tumor with grade 3 does not respond to platinum-based chemotherapy: a multicenter study of neuroendocrine carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S,

Keywords: NET-G3, NEC, KRAS, Rb,

#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors

Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Grabowski P

Authors: Grabowski P, Joehrens K, Arsenic R, Kaemmerer D, Hummel M,

Keywords: Immunophenotype, PD-L1, poorly differentiated NECs, immunotherapy,